Acorus Calamus Whole Citrullus Colocynthis Fruit P
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acorus Calamus Whole Citrullus Colocynthis Fruit P
- Multi-Ingredient Botanical Complex: Insufficient Data for Repurposing Analysis
Multi-Ingredient Botanical Complex: Insufficient Data for Repurposing Analysis
One-Sentence Summary
This entry represents a complex 10-ingredient botanical/herbal combination — including Colchicum autumnale bulb, Comfrey root, and Potassium iodide — that holds no US market authorization and carries no DrugBank identifier. The TxGNN model was unable to generate any repurposing predictions for this combination, as the multi-component mixture cannot be mapped to a unified drug identity in the knowledge graph. Without a matched DrugBank entry or approved indication, no evidence-supported new indication can be proposed at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indications on record |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 — model prediction not generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Safety Considerations
Although structured safety data is unavailable for this combination as a whole, several individual ingredients carry well-documented regulatory concerns that warrant attention before any further evaluation:
- Colchicum autumnale bulb contains colchicine alkaloids with a narrow therapeutic index; overdose can be life-threatening.
- Comfrey root (Symphytum officinale) contains pyrrolizidine alkaloids (PAs), classified as hepatotoxic and potentially carcinogenic. Oral use is banned or severely restricted in multiple jurisdictions (US FDA, EU, Germany BfR).
- Toxicodendron pubescens leaf (poison oak) can cause severe contact dermatitis; systemic toxicity risk must be evaluated for any non-topical route.
- Citrullus colocynthis is a potent cathartic with reports of hemorrhagic colitis and renal toxicity.
- Potassium iodide has documented interactions with thyroid function and certain cardiac medications.
A formal ingredient-by-ingredient toxicological review and drug interaction screening is required before this combination can proceed to any efficacy evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale: This 10-ingredient botanical combination cannot be processed by the TxGNN model due to the absence of a unified DrugBank entry, and no original or predicted indication exists to anchor a repurposing hypothesis. Several individual ingredients have known serious safety signals that must be resolved before efficacy work can begin.
To proceed, the following is needed:
- Identity resolution: Determine whether this combination corresponds to a registered product (e.g., homeopathic, traditional medicine, or compounded formulation) and obtain a product-level identifier.
- DrugBank mapping: Attempt individual-ingredient DrugBank lookups for components with known drug activity (e.g., colchicine from Colchicum autumnale, potassium iodide), then evaluate whether a single active ingredient can serve as the repurposing anchor.
- Safety pre-screen: Conduct a formal PA (pyrrolizidine alkaloid) safety assessment for Comfrey root and a colchicine toxicity review before any clinical translation is considered.
- Regulatory status clarification: Confirm whether this combination is intended as a homeopathic product, herbal supplement, or conventional drug formulation, as the regulatory pathway and evidence standards differ significantly.
- Re-run TxGNN: Once a primary active ingredient is identified and mapped, resubmit as a single-ingredient query to obtain a prediction score and disease ranking.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.